Roche Diagnostics partners to transform patient monitoring in hospitals

Diagnostics & MedTech News: Roche Diagnostics is gearing up to partner with a health technology company, with plans to roll out pilot hospital programs across the Asia Pacific region in early 2025. The collaboration between Singapore-based Respiree and Roche aims to improve patient monitoring by addressing inefficiencies in traditional hospital workflows.

Currently, diabetes patient monitoring often depends on nurses managing patients from centralised workstations. They collect vital signs and biomarkers at various intervals, but the manual nature of this process can become cumbersome, especially with limited workstations, rising patient volumes, and ongoing workforce shortages.

By combining Roche’s cutting-edge cobas pulse system, a next generation point-of-care (POC) blood glucose monitoring system, with Respiree’s vital sign monitoring technology, the pilot programs seek to offer a streamlined solution. What sets this system apart is its potential future integration of machine learning (ML) models that can predict clinical deterioration using historical data and risk scores directly at the patient’s bedside.

“The use of Respiree with the cobas pulse system has tremendous potential to enhance clinical workflows. Nurses can administer devices and view historical vitals in real-time without the need for centralised workstations, providing immediate bedside insights into patient progress,” said Dr Gurpreet Singh, CEO and Founder of Respiree.

“Additionally, nurses can automate the extraction and measurement of vitals from connected devices almost instantaneously, removing the need for manual scanning and measurements.”

The cobas pulse system, built on an Android platform, is the successor to the Accu-Chek Inform II. It enables real-time data visualisation and administration without the need for a centralised workstation.

Meanwhile, Respiree’s solution tracks multiple biometrics, including pulse rate, oxygen saturation, respiratory rate, temperature, and even ratios of inhalation-to-exhalation. Blood pressure readings can also be input manually, making the system a comprehensive tool for bedside monitoring.

With this combined technology, healthcare providers can monitor patients in real-time, directly at the bedside, without the need to return to workstations. Vital signs and blood sugar levels are measured simultaneously, and nurses can annotate clinical notes using the Respiree solution integrated within the cobas pulse system.

Respiree has already gained regulatory approvals from the Therapeutic Goods Administration (TGA) and the U.S. Food and Drug Administration (FDA), and is also CE marked.

With the healthcare industry increasingly stretched by workforce shortages and rising patient demands, the Respiree-Roche Diagnostics collaboration promises to offer a much-needed technological boost to hospitals, with the potential to reshape how care is delivered.

In reimagining healthcare, Health Industry Hub^TM is the ONLY one-stop-hub uniting the diversity of Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change. The exclusive leadership and influencer podcasts and vodcasts offer unparalleled insights and add immense value to our breaking news coverage.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.